Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 17 art units • 19 examiners • 0 of 19 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Sanford Burnham Prebys Medical Discovery Institute has 20 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 20 distinct examiners and 17 distinct art units, reflecting extensive distribution across the biotechnology examination landscape.
VAZ, JANICE EZVI is the busiest examiner, with 1 pending matter. No examiner concentration is shown in the data. Effective management will depend on centralized docket control and consistent scientific support, combined with response strategies tailored to the 17 art units.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 5 (26%) |
| §102 only | 2 (11%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 3 (16%) |
| Multi-statute (no §101) | 6 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAZ, JANICE EZVI | 1 | 76.3% | +20.3% |
| SAPKOTA, SURAJ | 1 | 0.0% | +0.0% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
| HILL, GRACELYN MARKHAM | 1 | 50.0% | +0.0% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710429 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17827584 | COMPOSITIONS AND METHODS FOR TREATING NERVOUS SYSTEM INJURIES | BRADLEY, CHRISTINA | 103d overdue |
| 17312855 | Models and Methods Useful for the Treatment of Serrated Colorectal Cancer | HOLTZMAN, KATHERINE ANN | 46d overdue |
| 18764707 | INHIBITION OF GLUTARYL-COA DEHYDROGENASE FOR THE TREATMENT OF MELANOMA | SAPKOTA, SURAJ | — |
| 18290749 | COMPOSITIONS AND METHODS FOR INHIBITING HUMAN BLOOD PROTEIN VITRONECTIN | MELCHIOR, JAMES RYLAND | — |
| 18273686 | SARS-COV-2 THERAPEUTICS | HERNANDEZ, JACKSON J | — |
| 18327715 | MICROSCOPIC IMAGING AND ANALYSES OF EPIGENETIC LANDSCAPE | HILL, GRACELYN MARKHAM | — |
| 18325745 | METHODS AND COMPOSITIONS FOR HAIR FOLLICLE GENERATION | WILSON, MICHAEL C | — |
| 17997757 | METHODS AND COMPOSITIONS FOR INDUCTION OF ANTITUMOR IMMUNITY | STONEBRAKER, ALYSSA RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18156984 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY INHIBITION OF FBXO44 | HOWARD, ZACHARY C | 34d |
| 19002503 | MACHINE-LEARNING SYSTEM FOR DIAGNOSING DISORDERS AND DISEASES AND DETERMINING DRUG RESPONSIVENESS | VAZ, JANICE EZVI | — |
| 18710429 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | WILLIS, DOUGLAS M | — |
| 18696213 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | O DELL, DAVID K | — |
| 18290749 | COMPOSITIONS AND METHODS FOR INHIBITING HUMAN BLOOD PROTEIN VITRONECTIN | MELCHIOR, JAMES RYLAND | — |
| 18273686 | SARS-COV-2 THERAPEUTICS | HERNANDEZ, JACKSON J | — |
| 18325745 | METHODS AND COMPOSITIONS FOR HAIR FOLLICLE GENERATION | WILSON, MICHAEL C | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1621 | 2 |
| 2667 | 1 |
| 1635 | 1 |
| 1644 | 1 |
| 1627 | 1 |
| 1656 | 1 |
| 1638 | 1 |
| 1658 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19002503 | MACHINE-LEARNING SYSTEM FOR DIAGNOSING DISORDERS AND DISEASES AND DETERMINING DRUG RESPONSIVENESS | VAZ, JANICE EZVI | 2667 | §112DP | Non-Final OA | — | Pending | Dec 26, 2024 |
| 18764707 | INHIBITION OF GLUTARYL-COA DEHYDROGENASE FOR THE TREATMENT OF MELANOMA | SAPKOTA, SURAJ | 1635 | §102§103§112 | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18710429 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | WILLIS, DOUGLAS M | 1624 | §112 | Final Rejection | — | Pending | May 15, 2024 |
| 18696213 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | O DELL, DAVID K | 1621 | §103 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18290749 | COMPOSITIONS AND METHODS FOR INHIBITING HUMAN BLOOD PROTEIN VITRONECTIN | MELCHIOR, JAMES RYLAND | 1644 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18273686 | SARS-COV-2 THERAPEUTICS | HERNANDEZ, JACKSON J | 1627 | §103§112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18327715 | MICROSCOPIC IMAGING AND ANALYSES OF EPIGENETIC LANDSCAPE | HILL, GRACELYN MARKHAM | 1656 | §101§102§112 | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18325745 | METHODS AND COMPOSITIONS FOR HAIR FOLLICLE GENERATION | WILSON, MICHAEL C | 1638 | §102§103§112 | Final Rejection | — | Pending | May 30, 2023 |
| 18172116 | COMPOSITIONS AND METHODS FOR TREATING DISEASES | STEELE, AMBER D | 1658 | §103§112DPOther | Non-Final OA | — | Pending | Feb 21, 2023 |
| 18156984 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY INHIBITION OF FBXO44 | HOWARD, ZACHARY C | 1674 | §103 | Non-Final OA | 34d | Pending | Jan 19, 2023 |
| 17928468 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | YOO, SUN JAE | 1621 | §102 | Final Rejection | 26d overdue | Pending | Nov 29, 2022 |
| 17997757 | METHODS AND COMPOSITIONS FOR INDUCTION OF ANTITUMOR IMMUNITY | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Final Rejection | — | Pending | Nov 02, 2022 |
| 17906818 | COMPOSITIONS AND METHODS FOR TREATING SERRATED COLORECTAL CANCER | CLARKE, TRENT R | 1651 | §103Other | Non-Final OA | 42d overdue | Pending | Sep 20, 2022 |
| 17799639 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | MCDOWELL, BRIAN E | 1624 | §102 | Non-Final OA | 29d | Pending | Aug 12, 2022 |
| 17799641 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | LEE, WILLIAM Y | 1623 | §112DP | Non-Final OA | 145d overdue | Pending | Aug 12, 2022 |
| 17827584 | COMPOSITIONS AND METHODS FOR TREATING NERVOUS SYSTEM INJURIES | BRADLEY, CHRISTINA | 1654 | §101§102§112Other | Non-Final OA | 103d overdue | Pending | May 27, 2022 |
| 17773775 | METABOLIC REPROGRAMMING OF IMMUNE CELLS TO ENHANCE THE EFFICACY OF PROPHYLACTIC AND THERAPEUTIC VACCINES | RICCI, CRAIG D | 1611 | §103 | Final Rejection | 97d overdue | Pending | May 02, 2022 |
| 17510887 | NOVEL BIOMOLECULE CONJUGATES AND USES THEREFOR | CESARE, JOSEPH DAVID | 1600 | §103 | Final Rejection | — | Pending | Oct 26, 2021 |
| 17312855 | Models and Methods Useful for the Treatment of Serrated Colorectal Cancer | HOLTZMAN, KATHERINE ANN | 1646 | §103§112Other | Final Rejection | 46d overdue | Pending | Jun 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSanford Burnham Prebys Medical Discovery Institute has 19 pending office actions as of October 2026, spread across 17 art units and 19 examiners.
Janice Ezvi Vaz has the most, with 1 of Sanford Burnham Prebys Medical Discovery Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
